Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Teresa L. Helsten"'
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Razelle Kurzrock, Scott M. Lippman, Paul T. Fanta, Julio Romero, Lyudmila A. Bazhenova, Teresa L. Helsten, Santosh Kesari, David E. Piccioni, Gregory A. Daniels, Richard B. Schwab, Barbara A. Parker, Maria Schwaederle
By profiling their patients' tumors, oncologists now have the option to use molecular results to match patients with drug(s) based on specific biomarkers. In this observational study, 347 patients with solid advanced cancers and next-generation seque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d38652e4f16dcdeda5f7bb5f11ff928f
https://doi.org/10.1158/1535-7163.c.6538405.v1
https://doi.org/10.1158/1535-7163.c.6538405.v1
Autor:
Razelle Kurzrock, Scott M. Lippman, Paul T. Fanta, Julio Romero, Lyudmila A. Bazhenova, Teresa L. Helsten, Santosh Kesari, David E. Piccioni, Gregory A. Daniels, Richard B. Schwab, Barbara A. Parker, Maria Schwaederle
Supplemental Methods 1) Sequencing: (182 and 236 gene lists) 2)Therapy 3) Matching Score 4) Statistical Analysis (patient's characteristics, study endpoints and definitions, analyses performed);Supplemental Table 1. Patient characteristics; Supplemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72e4f8a450bacecb9c256df081ef4ca4
https://doi.org/10.1158/1535-7163.22506457
https://doi.org/10.1158/1535-7163.22506457
Autor:
Jane Perlmutter, Gillian L. Hirst, A. Jo Chien, Anthony D. Elias, Andres Forero-Torres, Kevin Kalinsky, Julia Wulfkuhle, Ruby Singhrao, Lajos Pusztai, Nola M. Hylton, Richard Schwab, Smita Asare, Laura Sit, Hope S. Rugo, M. Melisko, Judy C. Boughey, Laura J. Esserman, Angela DeMichele, Laura J. van't Veer, Rebecca Shatsky, Scott M. Berry, Lili Du, Christina Yau, Ashish Sanil, D Yee, Adam Asare, Donald A. Berry, Kathy S. Albain, Amy S. Clark, Anne M. Wallace, Rita Nanda, Claudine Isaacs, Hyo S. Han, Denise M. Wolf, E. Petricoin, Minetta C. Liu, Teresa L. Helsten, Jeffrey B. Matthews, Amy Wilson, Erica Stringer-Reasor, Alexandra Thomas, W. Fraser Symmans, Heather Beckwith, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
SSRN Electronic Journal.
The combination of PD-L1-inhibitor durvalumab and PARP-inhibitor olaparib (DOP) in addition to standard neoadjuvant chemotherapy was investigated in the phase II I-SPY2 platform trial of stage II/III HER2-negative breast cancer. Seventy-three HER2-ne
Autor:
Yee, Douglas, Isaacs, Claudine, Wolf, Denise M., Yau, Christina, Haluska, Paul, Giridhar, Karthik V., Forero-Torres, Andres, Jo Chien, A., Wallace, Anne M., Pusztai, Lajos, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Kemmer, Kathleen, Yung, Rachel L., Pohlmann, Paula R., Tripathy, Debu
Publikováno v:
NPJ Breast Cancer; 10/5/2021, Vol. 7 Issue 1, p1-8, 8p
Autor:
Jane Perlmutter, Amy Wilson, W. Fraser Symmans, Denise M. Wolf, Paul Haluska, Christina Yau, Douglas Yee, Teresa Helsten, Richard Schwab, Nola M. Hylton, Laura J. van't Veer, Joan Venticinque, Angela DeMichele, Hope S. Rugo, Claudine Isaacs, Laura J. Esserman, Donald A. Berry, Michelle E. Melisko
Publikováno v:
Cancer Research. 81:PS4-08
I-SPY2 is a neoadjuvant trial evaluating experimental therapies in combination with cytotoxic chemotherapy compared to chemotherapy alone with the primary endpoint of pathologic complete response (pCR). Abundant preclinical evidence suggested the typ
Autor:
Molinolo A. Alfred, Richard Schwab, Barbara A. Parker, Karen Messer, Ruifeng Chen, James B. Breitmeyer, Laura Z. Rassenti, Teresa Helsten, Rebecca Shatsky, Emily Pittman, Elizabeth Weihe, Emmanuela M. Ghia, Catriona Jamieson, Thomas J. Kipps, George F. Widhopf
Publikováno v:
Cancer Research. 80:P3-10
Background: Cirmtuzumab is a humanized monoclonal antibody that targets the receptor tyrosine kinase like orphan receptor 1 (ROR1), which is expressed on poor prognosis breast cancer, ovarian cancer, other solid tumors, CLL and mantle cell lymphoma.
Autor:
Amy Wilson, Erica Stringer-Reasor, Jane Perlmutter, Christina Yau, Donald A. Berry, Kevin Kalinsky, Ashish Sanil, Kathy S. Albain, Hope S. Rugo, Teresa Helsten, Amy S. Clark, Laura J. Esserman, Erin D. Ellis, Angela DeMichele, Richard Schwab, Anthony D. Elias, Smita Asare, Nola M. Hylton, Michelle E. Melisko, Claudine Isaacs, Anne M. Wallace, Judy C. Boughey, Ruby Singhrao, Janice Lu, Douglas Yee, Julie E. Lang, Shelly S. Lo, Laura J. van't Veer, A. Jo Chien, W. Fraser Symmans
Publikováno v:
Cancer Research. 80:P3-11
Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents as neoadjuvant therapy for high-risk breast cancer. The primary endpoint is pathologic complete response (pCR)
Publikováno v:
Clinical Oncology Week; 6/20/2023, p1385-1385, 1p